Why the study?
Does the renin inhibitor remikiren affect hemodynamics, biochemical markers, and pharmacokinetics in healthy human subjects?
Population
Healthy human subjects
Comparison
Remikiren single ascending doses vs Placebo
Design
RCT, two-way crossover, double-blind
Authors
Loading...
Remikiren shows target engagement without acute hemodynamic effects in healthy subjects; extends pharmacodynamic profiling of renin inhibitors for patient trials.
Does the renin inhibitor remikiren affect hemodynamics, biochemical markers, and pharmacokinetics in healthy human subjects?
Remikiren is a potent renin inhibitor with dose-dependent biochemical effects and long-lasting action, but it does not produce acute hemodynamic changes in healthy subjects.
Kleinbloesem et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: